From CBC News:
The cancer drug Gleevec may carry a risk for decreased heart function, drug maker Novartis Pharmaceuticals warned Monday.
Gleevec or imatinib mesylate is used to treat adults with a type of blood cancer called chronic myeloid leukemia and a type of cancer of the stomach and bowels known as gastrointestinal stromal tumour. ...more
Links to the latest news in the world of pharmacy with a focus on items most relevant to Canadian pharmacists or others that are interested in Canadian pharmacies. This includes news about Canadian pharmacy seen in the mainstream media on topics such as new drug information and the international pharmacy industry.
Wednesday, October 04, 2006
Cancer drug may decrease heart function, company advises
Health Canada has recently issued advisories regarding the anticancer drug (imatinib mesylate (brand name Gleevec). Separate advisories are published for health professionals and the public.
No comments:
Post a Comment